Comparing Two Chemo Combos for Advanced Bile Duct Cancer
Part of Cancer clinical trials.
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have advanced bile duct or gallbladder cancer that cannot be removed by surgery, or it has come back after surgery.
- Your cancer got worse after at least one round of gemcitabine/cisplatin chemo, or you stopped it due to side effects.
- You have not been treated with oxaliplatin or irinotecan before.
- You have not had chemotherapy for advanced bile duct cancer beyond the first line.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This study compares two chemotherapy approaches for patients whose bile duct or gallbladder cancer has been removed but who have a higher chance of it coming back. One group gets a combination of two chemotherapy drugs through an IV, and the other gets a chemotherapy pill. The goal is to see which treatment better prevents recurrence.
This trial tests a combination of three drugs (irinotecan liposome, capecitabine, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has grown despite previous treatment. The goal is to see if this new combination can help shrink tumors or slow down the cancer.
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
Hear when a new Biliary Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.